| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/21/2013 | CN103251551A Injectable oxidized graphene or graphene composite hydrogel and preparation method thereof |
| 08/21/2013 | CN103251550A Transdermal delivery ointment containing colchicine, and preparation method thereof |
| 08/21/2013 | CN103250854A Cardiovascular disease-preventing sugar-free candy and preparation method thereof |
| 08/21/2013 | CN102813637B Kallidinogenase enteric coated tablet and preparation method thereof |
| 08/21/2013 | CN102784158B Preparation method of compound synergy tylosin tartrate for veterinary injection |
| 08/21/2013 | CN102772361B Medicament composition with docetaxel |
| 08/21/2013 | CN102716095B Paclitaxel vesicle type phospholipid gel injection |
| 08/21/2013 | CN102716085B Topotecan hydrochloride liposome injection |
| 08/21/2013 | CN102716075B Ceftizoxime sodium-containing pharmaceutical composition |
| 08/21/2013 | CN102697929B Hydrophilic Chinese medicinal patch and preparation method thereof |
| 08/21/2013 | CN102697765B Ranitidine hydrochloride/bismuth potassium citrate pharmaceutical composition solid lipid nanoparticles preparation |
| 08/21/2013 | CN102652736B Method for preparing soybean isoflavone sustained-release microspheres |
| 08/21/2013 | CN102614220B Preparing method of paracetamol, caffein, atificial cow-bezoar capsule content functional pellet |
| 08/21/2013 | CN102614124B Vaginal sterilizing foaming agent and preparation method thereof |
| 08/21/2013 | CN102579403B Duloxetine hydrochloride drug composition |
| 08/21/2013 | CN102579372B Gemcitabine hydrochloride lyophilized composition and preparation method thereof |
| 08/21/2013 | CN102552921B Montelukast sodium composition |
| 08/21/2013 | CN102552208B Daidzein solid dispersion micro-pill capsule and preparation method thereof |
| 08/21/2013 | CN102526129B Method for preparing Poria cocos granules by replacing part of auxiliary materials with ultrafine powder |
| 08/21/2013 | CN102512389B Fexofenadine hydrochloride oral disintegrating drug composition |
| 08/21/2013 | CN102499986B Macromolecule-cis-platinum compound, preparation method and application thereof |
| 08/21/2013 | CN102397557B Modification method for gold nanorods and gold nanorods-functional molecule composite |
| 08/21/2013 | CN102382231B Polyacrylic resin I and preparation method thereof |
| 08/21/2013 | CN102319212B Clevidipine butyrate structured lipid emulsion and preparation method thereof |
| 08/21/2013 | CN102231989B Ophthalmic device having therapeutic agent delivery capability and method of forming same |
| 08/21/2013 | CN102204891B Pharmaceutical formulation comprising a pyrimidine-A-one derivative coated with an enteric polymer |
| 08/21/2013 | CN102138899B Olmesartan liposome solid preparation |
| 08/21/2013 | CN102125534B Pantoprazole sodium enteric-coated capsule and preparation method thereof |
| 08/21/2013 | CN102114000B Co-feeding lipid nano-delivery system for medicine carrying |
| 08/21/2013 | CN102048693B Liposome having internal aqueous phases of benzenesulfonic acid derivatives |
| 08/21/2013 | CN101616935B Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers |
| 08/21/2013 | CN101600476B Punctal plugs and methods of delivering therapeutic agents |
| 08/21/2013 | CN101583629B Modified saccharides |
| 08/21/2013 | CN101573382B Monoclonal antibodies and directed against the human anti-mullerian hormone type ii receptor (amhr-ii) |
| 08/21/2013 | CN101500572B Solid compositions comprising tadalafil and at least one carrier |
| 08/21/2013 | CN101389323B Pharmaceutical composition comprising oseltamivir phosphate |
| 08/20/2013 | US8513392 Conjugation of streptococcal capsular saccharides |
| 08/20/2013 | US8513304 Topical formulation |
| 08/20/2013 | US8513300 Allergic rhinitis, asthma, rheumatoid arthritis or an autoimmune disease; Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) as delivery agent |
| 08/20/2013 | US8513225 Composition and method for topical treatment of skin lesions |
| 08/20/2013 | US8513183 Peptide pharmaceutical for oral delivery |
| 08/20/2013 | US8512787 Process for manufacturing chewable dosage forms for drug delivery and products thereof |
| 08/20/2013 | US8512770 Skin penetration composition |
| 08/20/2013 | US8512767 Pharmaceutical compositions |
| 08/20/2013 | US8512757 Micelles for drug delivery |
| 08/20/2013 | US8512749 Providing in situ tissue fluid leak sealants and/or drug delivery depots; crosslinks to form insoluble implant upon exposure to physiological environment; simple, inexpensive; effective in presence of anticoagulants |
| 08/20/2013 | US8512748 Controlled release system and method for manufacturing the same |
| 08/20/2013 | US8512744 Sustained release micropellets and process for producing the same |
| 08/20/2013 | US8512739 Use of low-glycemic sweeteners in food and beverage compositions |
| 08/20/2013 | US8512736 Coatings including natural biodegradable polysaccharides and uses thereof |
| 08/20/2013 | US8512723 Decontamination of vegetables, meats or fruits by disinfection of such with antimicrobial solution containing lipid and enhancer such as bacteriocins, sugars and enzymes |
| 08/20/2013 | US8512718 Pharmaceutical composition for topical application |
| 08/20/2013 | US8512693 Self-assembling membranes and related methods thereof |
| 08/20/2013 | US8512692 Methods of treating multiple sclerosis with stable liquid interferon-beta formulations |
| 08/20/2013 | US8512691 Stable liquid interferon-beta formulations |
| 08/20/2013 | CA2634232C Method of producing solid preparation disintegrating in the oral cavity |
| 08/20/2013 | CA2477794C System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 08/20/2013 | CA2398723C Pharmaceutical composition comprising carriers for products based on vitamin-e, papain and hyaluronidase |
| 08/15/2013 | WO2013119974A1 Aqueous pharmaceutical composition with enhanced stability |
| 08/15/2013 | WO2013119794A1 Modified release formulations of viloxazine |
| 08/15/2013 | WO2013119551A1 Multi-layer biomaterial for tissue regeneration and wound healing |
| 08/15/2013 | WO2013119304A2 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
| 08/15/2013 | WO2013119231A1 Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings |
| 08/15/2013 | WO2013119183A1 Methods of manufacturing core-shell microparticles, and microparticles formed thereof |
| 08/15/2013 | WO2013119061A1 Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same |
| 08/15/2013 | WO2013117963A1 Stable oral tablet dosage form of an antidiabetic compound |
| 08/15/2013 | WO2013117735A1 Conjugate comprising an agent and an antiviral ligand and its use in a method for delivering the agent intracellularly |
| 08/15/2013 | WO2013117560A1 Coated devices and methods for coating |
| 08/15/2013 | WO2013095042A3 Granule containing imatinib mesylate, immediate release oral tablet composition containing same, and preparation method thereof |
| 08/15/2013 | WO2013093705A3 Improved processes for preparing peptide conjugates and linkers |
| 08/15/2013 | WO2013093524A3 Method for preparing amorphous precipitated protein particles |
| 08/15/2013 | WO2013072686A3 Self-assembling peptides and hydrogels comprising them |
| 08/15/2013 | WO2013019930A3 Decomposable apparatus and methods for fabricating same |
| 08/15/2013 | US20130211368 Microfabricated nanopore device for sustained release of therapeutic agent |
| 08/15/2013 | US20130211353 Percutaneous absorption type formulation |
| 08/15/2013 | US20130211352 Percutaneously absorbed preparation |
| 08/15/2013 | US20130211060 Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| 08/15/2013 | US20130211049 Immunotoxin fusion proteins and means for expression thereof |
| 08/15/2013 | US20130211012 Carrier Nanoparticles and Related Compositions, Methods and Systems |
| 08/15/2013 | US20130210960 Calcium particle-embedded, snap-to-dough, high-viscosity bone cement |
| 08/15/2013 | US20130210934 Flavoring agents containing bio-derived 1,3-propanediol and its conjugate esters |
| 08/15/2013 | US20130210932 Novel cationic thickeners usable over a wide ph range, method for the preparation thereof, and composition containing same |
| 08/15/2013 | US20130210922 Stable ready to use injectable paracetamol formulation |
| 08/15/2013 | US20130210921 Method for Giving Warmth to Skin |
| 08/15/2013 | US20130210912 Ophthalmic Pharmaceutical Compositions and Methods of Making and Using Same |
| 08/15/2013 | US20130210908 Stabilized anthocyanin compositions |
| 08/15/2013 | US20130210896 Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System |
| 08/15/2013 | US20130210891 Pharmaceutical composition for transcolonic absorption |
| 08/15/2013 | US20130210879 Formulations of bendamustine |
| 08/15/2013 | US20130210878 Bendamustine compositions and methods therefore |
| 08/15/2013 | US20130210812 Aqueous Pharmaceutical Composition With Enhanced Stability |
| 08/15/2013 | US20130210762 Solid pharmaceutical composition for neutralizing stomach acid |
| 08/15/2013 | US20130210747 Methods and Therapeutics Comprising Ligand-Targeted ELPs |
| 08/15/2013 | US20130210744 Targeting agent for cancer cell or cancer-associated fibroblast |
| 08/15/2013 | US20130210742 Sustained-release formulation |
| 08/15/2013 | US20130210735 Emd formulation comprising pga |
| 08/15/2013 | US20130210729 Non-aqueous oily injectable formulation exhibiting preservative efficacy |
| 08/15/2013 | US20130210724 Cyclodextrin-Based Polymers for Therapeutic Delivery |
| 08/15/2013 | US20130210722 Methods for using peptide agonists having glp-1 activity |
| 08/15/2013 | US20130210714 Protein-bound tryptophan food composition |